DEA Lookup.com News
Return to News Home

Lifetime Risk of Developing or Dying From Cancer

According to the American Cancer Society, 1 in 2 men and 1 in 3 women alive today will get cancer during their lifetime.

Cancer.org, Mar 23, 2017

The lifetime risk of developing or dying from cancer refers to the chance a person has, over the course of his or her lifetime (from birth to death), of being diagnosed with or dying from cancer. These risk estimates, like annual incidence and mortality data, provide another measure of how widespread cancer is in the United States.

The following tables list lifetime risks of developing and dying from certain cancers for men and women. The information is from the US National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Database, and is based on incidence and mortality data for the United States from 2010 through 2012, the most current years for which data are available.

The risk is expressed both in terms of a percentage and as odds. For example, the risk that a man will develop bladder cancer during his lifetime is 3.84%. This means he has about 1 chance in 26 of developing bladder cancer (100/3.84 = 26.1). Put another way, 1 out of every 26 men in the United States will develop bladder cancer during his lifetime.

These numbers are average risks for the overall US population. Your risk may be higher or lower than these numbers, depending on your particular risk factors.

Males

Risk of developing

Risk of dying from

%

1 in

%

1 in

All invasive sites

42.05

2

22.62

4

Bladder (includes in situ)

3.84

26

0.92

109

Brain and nervous system

0.69

145

0.51

196

Breast

0.13

769

0.03

3,333

Colon and rectum

4.69

21

1.99

50

Esophagus

0.80

125

0.79

127

Hodgkin disease

0.24

417

0.04

2,500

Kidney and renal pelvis

2.03

49

0.62

161

Larynx (voice box)

0.59

169

0.20

500

Leukemia

1.75

57

1.03

97

Liver and bile duct

1.31

76

0.94

106

Lung and bronchus

7.19

14

6.33

16

Melanoma of the skin

2.62

38

0.43

233

Multiple myeloma

0.85

118

0.47

213

Non-Hodgkin lymphoma

2.37

42

0.86

116

Oral cavity and pharynx

1.55

65

0.40

250

Pancreas

1.54

65

1.37

73

Prostate

13.97

7

2.58

39

Stomach

1.07

93

0.48

208

Testicles

0.38

263

0.02

5,000

Thyroid

0.59

169

0.06

1,667

Females

Risk of developing

    Risk of dying from

%

1 in

%

1 in

All invasive sites

37.58

3

19.13

5

    Bladder (includes in situ)

    1.14

    88

    0.34

    294

    Brain and nervous system

    0.54

    185

    0.40

    250

    Breast

    12.32

    8

    2.69

    37

    Cervix

    0.64

    156

    0.23

    435

    Colon and rectum

    4.35

    23

    1.81

    55

    Esophagus

    0.22

    455

    0.21

    476

    Hodgkin disease

    0.20

    500

    0.03

    3,333

    Kidney and renal pelvis

    1.20

    83

    0.34

    294

    Larynx (voice box)

    0.13

    769

    0.05

    2,000

    Leukemia

    1.22

    82

    0.72

    139

    Liver and bile duct

    0.54

    185

    0.49

    204

    Lung and bronchus

    6.04

    17

    4.89

    20

    Melanoma of the skin

    1.63

    61

    0.21

    476

    Multiple myeloma

    0.64

    156

    0.39

    256

    Non-Hodgkin lymphoma

    1.89

    53

    0.68

    147

    Oral cavity and pharynx

    0.67

    149

    0.18

    556

    Ovary

    1.31

    76

    0.97

    103

    Pancreas

    1.50

    67

    1.34

    75

    Stomach

    0.66

    152

    0.32

    313

    Thyroid

    1.72

    58

    0.07

    1,429

    Uterine corpus

    2.78

    36

    0.58

    172

Return to News Home